Please assess the completion status of the following clinical trial:

Trial Title: Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent form and data protection declaration obtained prior to any trial-specific procedures~2. Patient aged ≥18 years~3. Confirmed diagnosis of post-thrombotic syndrome defined as Villalta score \> 4 points prior to enrolment and venous stent intervention~4. Confirmed stenosis of inferior vena cava, iliac vein, or common femoral vein by duplex ultrasound or cross-sectional imaging (CT venography or MR venography) prior to enrolment and venous stent intervention~5. Successfully conducted venous stent intervention involving either:~   * inferior vena cava~  * iliac vein or~  * common femoral vein~6. Patients either on active treatment with rivaroxaban or patients planned for treatment with rivaroxaban after intervention~Exclusion Criteria:~1. Previous venous intervention in target vessels~2. Any contraindication for antithrombotic therapy (e.g. active gastric ulcer, duodenal ulcer, bleeding disorder with increased tendency of bleedings)~3. Patients with a recent (3 months) clinically significant bleeding and / or active or recent (3 months) ulcerative or inflammatory gastrointestinal disease~4. Ongoing antiplatelet therapy or previous antiplatelet therapy within 7 days prior to Visit 1~5. Acute thrombosis (venous thromboembolism events \< 3 months prior to Visit 1)~6. Pre-existing coagulopathy~7. Prior stroke or transient ischemic attack (\< 12 months prior to Visit 1)~8. Pregnancy, breast feeding, or planned pregnancy within the trial period or women of childbearing potential not using an adequate method of contraception~9. Severe heart, liver or kidney disease~10. Severe somatopathic, neurological and / or psychiatric disease(s)~11. Malignant growth (concurrent or previous cancer with a relapse-free and treatment-free interval of less than 5 years before Visit 1)~12. Known hypersensitivity to acetylsalicylic acid (Aspirin® cardio or Aspirin® protect and / or its excipients), to other antiphlogistic drugs or to analgesics or anti-fever drugs~13. Concomitant intake of Methotrexat \> 15 mg per week~14. Parallel participation in another clinical trial, participation in a clinical trial within less than 6 weeks prior to the Screening visit or previous participation in this clinical trial~15. Known to be, or suspected of being unable to comply with the trial protocol (e.g. no permanent address, history of drug abuse, known to be non-compliant or presenting an unstable psychiatric history)~16. Legal incapacity and / or other circumstances rendering the patient unable to understand the nature, scope and possible impact of the study~17. Custody by juridical or official order~18. Evidence of an uncooperative attitude~19. Difficulties in understanding the language in which the patient information is given~20. Patients dependent from the investigator or sponsor (e.g. close relatives of the investigator, employees of the clinic, the sponsor or involved CRO(s))

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin® (Type: EXPERIMENTAL): To show if a combination therapy of rivaroxaban plus Aspirin® is more efficient (superiority testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy.~To demonstrate tolerability of combination therapy of Aspirin® plus rivaroxaban in long-term treatment.
- Control group (Type: NO_INTERVENTION): Observational study of standard of care anticoagulation (rivarobaban dosis defined in the clinical routine).

Based on this trial design, predict the completion outcome and termination type (if applicable).